Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Nassar Junior, Antonio Paulo ^a   Farias, Alberto Queiroz ^a   D'Albuquerque, Luiz Augusto Carneiro ^a   Carrilho, Flair José ^a   Malbouisson, Luiz Marcelo Sá ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN; TERLIPRESSIN; LYPRESSIN; VASOCONSTRICTOR AGENT;

ABDOMINAL CRAMP; CYANOSIS; DEFECATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXTRASYSTOLE; HEART VENTRICLE EXTRASYSTOLE; HEPATORENAL SYNDROME; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SIDE EFFECT; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THORAX PAIN; ANALOGS AND DERIVATIVES; MIDDLE AGED; TREATMENT OUTCOME;

HEPATORENAL SYNDROME; HUMANS; LYPRESSIN; MIDDLE AGED; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 84925808474     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107466     Document Type: Review

References (23)

1. Arroyo V, Fernandez J (2011) Management of hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol 7: 517-526.
2. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, et al. (2011) Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 55: 1241-1248.
3. Carvalho GC, Regis Cde A, Kalil JR, Cerqueira LA, Barbosa DS, et al. (2012) Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Ann Hepatol 11: 90-95.
4. Gluud LL, Christensen K, Christensen E, Krag A (2012) Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 9: CD005162.
5. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, et al. (2002) Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 36: 374-380.
6. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
7. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
8. Wallace BC, Schmid CH, Lau J, Trikalinos TA (2009) Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 9: 80.
9. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, et al. (2007) Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 47: 499-505.
10. Sharma P, Kumar A, Shrama BC, Sarin SK (2008) An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103: 1689-1697.
11. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, et al. (2012) Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 56: 1293-1298.
12. Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, et al. (2013) Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int 33: 1187-1193.
13. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23: 164-176.
14. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310-1318.
15. Angeli P, Gines P (2012) Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 57: 1135-1140.
16. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, et al. (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105: 229-236.
17. Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, et al. (2009) Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 24: 1791-1797.
18. Kiszka-Kanowitz M, Henriksen JH, Hansen EF, Moller S, Bendtsen F (2004) Effect of terlipressin on blood volume distribution in patients with cirrhosis. Scand J Gastroenterol 39: 486-492.
19. Dobre M, Demirjian S, Sehgal AR, Navaneethan SD (2011) Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis. Int Urol Nephrol 43: 175-184.
20. Hiremath SB, Srinivas LD (2013) Survival benefits of terlipressin and nonresponder state in hepatorenal syndrome: a meta-analysis. Indian J Pharmacol 45: 54-60.
21. Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A, et al. (2008) Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 134: 1352-1359.
22. Nazar A, Pereira GH, Guevara M, Martin-Llahi M, Pepin MN, et al. (2010) Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 51: 219-226.
23. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, et al. (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360-1368.